Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1671-1678

  Galagudza, Michael ^a   Korolev, Dmitry ^a   Postnov, Viktor ^b   Naumisheva, Elena ^b   Grigorova, Yulia ^c   Uskov, Ivan ^a   Shlyakhto, Eugene ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

^b ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Ischemia; Myocardium; Reperfusion; Silica nanoparticles; Targeted drug delivery

Indexed keywords

ADENOSINE; NANOPARTICLE; SILICA NANOPARTICLE; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; DRUG CARRIER; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG STABILITY; DRUG TARGETING; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEMODYNAMIC MONITORING; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOPHARMACEUTICS; NONHUMAN; RAT; SURFACE PROPERTY; ANIMAL; BLOOD PRESSURE; HEART INFARCTION; NANOMEDICINE; PATHOLOGY; PATHOPHYSIOLOGY; REPERFUSION INJURY; TISSUE DISTRIBUTION; WISTAR RAT;

RATTUS;

ADENOSINE; ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NANOMEDICINE; NANOPARTICLES; RATS; RATS, WISTAR; SILICON DIOXIDE; TISSUE DISTRIBUTION;

EID: 84866751517     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29511     Document Type: Article

References (32)

1. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol. 2011;301(5):H1723-H1741.
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-1135.
3. Galagudza M, Kurapeev D, Minasian S, Valen G, Vaage J. Ischemic postconditioning: brief ischemia during reperfusion converts persistent ventricular fibrillation into regular rhythm. Eur J Cardiothorac Surg. 2004;25(6):1006-1010.
4. Zhao ZQ. Postconditioning in reperfusion injury: a status report. Cardiovasc Drugs Ther. 2010;24(3):265-279.
5. Galagudza MM, Blokhin IO, Shmonin AA, Mischenko KA. Reduction of myocardial ischemia-reperfusion injury with pre-and postconditioning: molecular mechanisms and therapeutic targets. Cardiovasc Hematol Disord Drug Targets. 2008;8(1):47-65.
6. Ye X, Yang D. Recent advances in biological strategies for targeted drug delivery. Cardiovasc Hematol Disord Drug Targets. 2009;9(3): 206-221.
7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986;46(12 Pt 1):6387-6392.
8. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug delivery systems for cancer treatment. Curr Drug Targets. 2011;12(8):1151-1165.
9. Hirsjarvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol. 2011;8(3):188-196.
10. Scott RC, Rosano JM, Ivanov Z, et al. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009;23(10):3361-3367.
11. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J Drug Target. 2006;14(5):273-280.
12. Galagudza MM, Korolev DV, Sonin DL, et al. Targeted drug delivery into reversibly injured myocardium with silica nanoparticles: surface functionalization, natural biodistribution, and acute toxicity. Int J Nanomedicine. 2010;5:231-237.
13. Donato M, D'Annunzio V, Berg G, et al. Ischemic postconditioning reduces infarct size by activation of A1 receptors and Kr(ATP) channels in both normal and hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2007;49(5):287-292.
14. Xi L, Das A, Zhao ZQ, et al. Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation. 2008;118(14):S32-S37.
15. Morrison RR, Tan XL, Ledent C, Mustafa SJ, Hofmann PA. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol. 2007;293(4):H2523-H2529.
16. Xi J, McIntosh R, Shen X, et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol. 2009;47(5):684-690.
17. Norton ED, Jackson EK, Turner MB, Virmani R, Forman MB. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J. 1992;123(2):332-338.
18. Pantely GA, Bristow JD. Adenosine. Renewed interest in an old drug. Circulation. 1990;82(5):1854-1856.
19. Finnie KS, Waller DJ, Perret FL, et al. Biodegradability of sol-gel silica microparticles for drug delivery. J Sol-Gel Sci Technol. 2009;49: 12-18.
20. Takahama H, Minamino T, Asanuma H, et al. Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J Am Coll Cardiol. 2009;53(8):709-717.
21. Homma T, Irvin CG. Bradykinin-induced bronchospasm in the rat in vivo: a role for nitric oxide modulation. Eur Respir J. 1999;13(2): 313-320.
22. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359(5): 473-481.
23. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res. 2005;22(12):2115-2120.
24. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53(1):31-47.
25. Okamura A, Ito H, Iwakura K, et al. Effect of reactive hyperemia after coronary recanalization on myocardial tissue reperfusion by thrombolysis in myocardial infarction flow grade in acute myocardial infarction. Am J Cardiol. 2006;97(5):617-623.
26. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278-1288.
27. Kumar R, Roy I, Ohulchanskky TY, et al. In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano. 2010;4(2):699-708.
28. Xie G, Sun J, Zhong G, Shi L, Zhang D. Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Arch Toxicol. 2010;84(3):183-190.
29. Nishimori H, Kondoh M, Isoda K, et al. Silica nanoparticles as hepatotoxicants. Eur J Pharm Biopharm. 2009;72(3):496-501.
30. Nishimori H, Kondoh M, Isoda K, et al. Histological analysis of 70-nm silica particles-induced chronic toxicity in mice. Eur J Pharm Biopharm. 2009;72(3):626-629.
31. Cho M, Cho WS, Choi M, et al. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett. 2009;189(3):177-183.
32. Isoda K, Hasezaki T, Kondoh M, Tsutsumi Y, Yagi K. Effect of surface charge on nano-sized silica particle-induced liver injury. Pharmazie. 2011;66(4):278-281.